Here's how LINK.SPRINGER.COM makes money* and how much!

*Please read our disclaimer before using our estimates.
Loading...

LINK . SPRINGER . COM {}

  1. Analyzed Page
  2. Matching Content Categories
  3. CMS
  4. Monthly Traffic Estimate
  5. How Does Link.springer.com Make Money
  6. Keywords
  7. Topics
  8. Questions
  9. Schema
  10. External Links
  11. Analytics And Tracking
  12. Libraries
  13. CDN Services

We are analyzing https://link.springer.com/article/10.1186/bcr3242.

Title:
Persistence of disseminated tumor cells after neoadjuvant treatment for locally advanced breast cancer predicts poor survival | Breast Cancer Research
Description:
Introduction Presence of disseminated tumor cells (DTCs) in bone marrow (BM) and circulating tumor cells (CTC) in peripheral blood (PB) predicts reduced survival in early breast cancer. The aim of this study was to determine the presence of and alterations in DTC- and CTC-status in locally advanced breast cancer patients undergoing neoadjuvant chemotherapy (NACT) and to evaluate their prognostic impact. Methods Bone marrow and peripheral blood were collected before NACT (BM1: n = 231/PB1: n = 219), at surgery (BM2: n = 69/PB2: n = 71), and after 12 months from start of NACT (BM3: n = 162/PB3: n = 141). Patients were included from 1997 to 2003 and followed until 2009 (or ten years follow-up). DTC- and CTC-status were determined by morphological evaluation of immunocytochemically detected cytokeratin-positive cells. The prognostic significance of DTCs/CTCs was assessed by univariate and multivariate Cox-regression analyses. Results Before NACT, DTCs and CTCs were detected in 21.2% and 4.9% of the patients, respectively. At surgery, 15.9% and 1.4% had DTC- and CTC-presence, compared to 26.5% and 4.3% at 12 months from start of NACT. Of patients for whom DTC results both before NACT and at 12 months were available, concordant results were observed in 68%, and 14 out of 65 had positive DTC-status at both time points. Presence of ≥ 1 DTC 12 months from start of NACT, but not at other time points, predicted reduced disease-free survival (DFS; HR 2.3, p = 0.003), breast cancer-specific survival (BCSS; HR 3.0, p < 0.001) and overall survival (OS; HR 2.8, p < 0.001). Before NACT, presence of ≥ 3 DTCs was also associated with unfavorable outcome, and reduced BCSS was observed for CTC-positive patients (HR 2.2, p = 0.046). In multivariate analysis, DTC status (</≥ 1 DTC) at 12 months after start of NACT remained as a prognostic factor for both DFS (HR 2.2, p = 0.005), BCSS (HR 2.6, p = 0.002) and OS (HR 2.6, p = 0.002). The survival for patients with change in DTC-status was determined by the DTC-status at 12 months. Conclusion Presence of DTCs after NACT indicated high risk for relapse and death, irrespective of the DTC-status before treatment. The results supports the potential use of DTC analysis as a monitoring tool during follow up, for selection of patients to secondary treatment intervention within clinical trials.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

  • Science
  • Health & Fitness
  • Education

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month


Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We're unsure how the site profits.

Many websites are intended to earn money, but some serve to share ideas or build connections. Websites exist for all kinds of purposes. This might be one of them. Link.springer.com has a secret sauce for making money, but we can't detect it yet.

Keywords {🔍}

cancer, patients, breast, tumor, cells, dtcs, pubmed, article, survival, dtc, google, scholar, study, treatment, results, cas, bone, analysis, marrow, chemotherapy, time, presence, bcss, status, primary, detection, nact, clinical, table, ctcs, disseminated, neoadjuvant, blood, prognostic, dfs, circulating, analyses, surgery, response, number, figure, advanced, months, university, aspiration, clin, res, central, locally, peripheral,

Topics {✒️}

neoadjuvant anthracycline-taxane-based chemotherapy article download pdf breast cancer-specific survival ficoll-hypaque density centrifugation cytokeratin-19 mrna-positive cells open-labeled multicenter study real-time rt-pcr detection multivariate cox-regression analyses epithelial-mesenchymal transition markers full size image breast cancer-specific death kaplan-meier survival curves locally advanced disease predicts reduced survival advanced breast cancer cytokeratin-positive cells detected monoclonal anti-alkaline phosphatase long-term prognostic impact metastatic breast cancer early breast cancer minimal residual disease kaplan-meier plot shown blood-circulating tumour cells operable breast cancer disease-free survival full access disseminated tumor cell genome-based molecular characterization norwegian cancer society high-risk group high risk group primary breast cancer breast cancer res tumor cell-shedding single tumor cell inflammatory breast cancer breast cancer prognostication breast cancer progresses privacy choices/manage cookies natl cancer inst single-cell sequencing authors’ original file median relapse-free follow tumour cell detection breast cancer patients locally advanced breast cancer death article number r117 unfavorable tumor biology dtc-negative group

Questions {❓}

  • Does primary neoadjuvant systemic therapy eradicate minimal residual disease?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Persistence of disseminated tumor cells after neoadjuvant treatment for locally advanced breast cancer predicts poor survival
         description:Presence of disseminated tumor cells (DTCs) in bone marrow (BM) and circulating tumor cells (CTC) in peripheral blood (PB) predicts reduced survival in early breast cancer. The aim of this study was to determine the presence of and alterations in DTC- and CTC-status in locally advanced breast cancer patients undergoing neoadjuvant chemotherapy (NACT) and to evaluate their prognostic impact. Bone marrow and peripheral blood were collected before NACT (BM1: n = 231/PB1: n = 219), at surgery (BM2: n = 69/PB2: n = 71), and after 12 months from start of NACT (BM3: n = 162/PB3: n = 141). Patients were included from 1997 to 2003 and followed until 2009 (or ten years follow-up). DTC- and CTC-status were determined by morphological evaluation of immunocytochemically detected cytokeratin-positive cells. The prognostic significance of DTCs/CTCs was assessed by univariate and multivariate Cox-regression analyses. Before NACT, DTCs and CTCs were detected in 21.2% and 4.9% of the patients, respectively. At surgery, 15.9% and 1.4% had DTC- and CTC-presence, compared to 26.5% and 4.3% at 12 months from start of NACT. Of patients for whom DTC results both before NACT and at 12 months were available, concordant results were observed in 68%, and 14 out of 65 had positive DTC-status at both time points. Presence of ≥ 1 DTC 12 months from start of NACT, but not at other time points, predicted reduced disease-free survival (DFS; HR 2.3, p = 0.003), breast cancer-specific survival (BCSS; HR 3.0, p &lt; 0.001) and overall survival (OS; HR 2.8, p &lt; 0.001). Before NACT, presence of ≥ 3 DTCs was also associated with unfavorable outcome, and reduced BCSS was observed for CTC-positive patients (HR 2.2, p = 0.046). In multivariate analysis, DTC status (&lt;/≥ 1 DTC) at 12 months after start of NACT remained as a prognostic factor for both DFS (HR 2.2, p = 0.005), BCSS (HR 2.6, p = 0.002) and OS (HR 2.6, p = 0.002). The survival for patients with change in DTC-status was determined by the DTC-status at 12 months. Presence of DTCs after NACT indicated high risk for relapse and death, irrespective of the DTC-status before treatment. The results supports the potential use of DTC analysis as a monitoring tool during follow up, for selection of patients to secondary treatment intervention within clinical trials.
         datePublished:2012-08-14T00:00:00Z
         dateModified:2012-08-14T00:00:00Z
         pageStart:1
         pageEnd:13
         license:http://creativecommons.org/licenses/by/2.0/
         sameAs:https://doi.org/10.1186/bcr3242
         keywords:
            Overall Survival
            Advanced Breast Cancer
            Circulate Tumor Cell
            Bone Marrow Aspiration
            Disseminate Tumor Cell
            Cancer Research
            Oncology
            Surgical Oncology
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fbcr3242/MediaObjects/13058_2012_3049_Fig1_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fbcr3242/MediaObjects/13058_2012_3049_Fig2_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fbcr3242/MediaObjects/13058_2012_3049_Fig3_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fbcr3242/MediaObjects/13058_2012_3049_Fig4_HTML.jpg
         isPartOf:
            name:Breast Cancer Research
            issn:
               1465-542X
            volumeNumber:14
            type:
               Periodical
               PublicationVolume
         publisher:
            name:BioMed Central
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Randi R Mathiesen
               affiliation:
                     name:Institute for Cancer Research, Oslo University Hospital, The Radium Hospital
                     address:
                        name:Department of Genetics, Institute for Cancer Research, Oslo University Hospital, The Radium Hospital, Oslo, Norway
                        type:PostalAddress
                     type:Organization
                     name:Oslo University Hospital
                     address:
                        name:Division of Surgery and Cancer Medicine, Department of Oncology, Oslo University Hospital, Oslo, Norway
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Elin Borgen
               affiliation:
                     name:Oslo University Hospital, The Radium Hospital
                     address:
                        name:Department of Pathology, Oslo University Hospital, The Radium Hospital, Oslo, Norway
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Anne Renolen
               affiliation:
                     name:Oslo University Hospital, The Radium Hospital
                     address:
                        name:Department of Pathology, Oslo University Hospital, The Radium Hospital, Oslo, Norway
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Erik Løkkevik
               affiliation:
                     name:Oslo University Hospital
                     address:
                        name:Division of Surgery and Cancer Medicine, Department of Oncology, Oslo University Hospital, Oslo, Norway
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Jahn M Nesland
               affiliation:
                     name:Oslo University Hospital, The Radium Hospital
                     address:
                        name:Department of Pathology, Oslo University Hospital, The Radium Hospital, Oslo, Norway
                        type:PostalAddress
                     type:Organization
                     name:University of Oslo
                     address:
                        name:Institute of Clinical medicine, Faculty of Medicine, University of Oslo, Oslo, Norway
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Gun Anker
               affiliation:
                     name:University of Bergen
                     address:
                        name:Section of Oncology, Institute of Medicine, University of Bergen, Bergen, Norway
                        type:PostalAddress
                     type:Organization
                     name:Haukeland University Hospital
                     address:
                        name:Department of Oncology, Haukeland University Hospital, Bergen, Norway
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Bjørn Østenstad
               affiliation:
                     name:Oslo University Hospital
                     address:
                        name:Division of Surgery and Cancer Medicine, Department of Oncology, Oslo University Hospital, Oslo, Norway
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Steinar Lundgren
               affiliation:
                     name:St. Olav University Hospital
                     address:
                        name:Department of Oncology, St. Olav University Hospital, Trondheim, Norway
                        type:PostalAddress
                     type:Organization
                     name:Norwegian University of Science and Technology
                     address:
                        name:Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Terje Risberg
               affiliation:
                     name:University Hospital of Northern Norway and Institute of Clinical Medicine, University of Tromsø
                     address:
                        name:Department of Oncology, University Hospital of Northern Norway and Institute of Clinical Medicine, University of Tromsø, Tromsø, Norway
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Ingvil Mjaaland
               affiliation:
                     name:Stavanger University Hospital
                     address:
                        name:Division of Hematology and Oncology, Stavanger University Hospital, Stavanger, Norway
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Gunnar Kvalheim
               affiliation:
                     name:Oslo University Hospital
                     address:
                        name:Division of Surgery and Cancer Medicine, Department of Oncology, Oslo University Hospital, Oslo, Norway
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Per Eystein Lønning
               affiliation:
                     name:University of Bergen
                     address:
                        name:Section of Oncology, Institute of Medicine, University of Bergen, Bergen, Norway
                        type:PostalAddress
                     type:Organization
                     name:Haukeland University Hospital
                     address:
                        name:Department of Oncology, Haukeland University Hospital, Bergen, Norway
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Bjørn Naume
               affiliation:
                     name:Oslo University Hospital
                     address:
                        name:Division of Surgery and Cancer Medicine, Department of Oncology, Oslo University Hospital, Oslo, Norway
                        type:PostalAddress
                     type:Organization
                     name:University of Oslo
                     address:
                        name:Institute of Clinical medicine, Faculty of Medicine, University of Oslo, Oslo, Norway
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Persistence of disseminated tumor cells after neoadjuvant treatment for locally advanced breast cancer predicts poor survival
      description:Presence of disseminated tumor cells (DTCs) in bone marrow (BM) and circulating tumor cells (CTC) in peripheral blood (PB) predicts reduced survival in early breast cancer. The aim of this study was to determine the presence of and alterations in DTC- and CTC-status in locally advanced breast cancer patients undergoing neoadjuvant chemotherapy (NACT) and to evaluate their prognostic impact. Bone marrow and peripheral blood were collected before NACT (BM1: n = 231/PB1: n = 219), at surgery (BM2: n = 69/PB2: n = 71), and after 12 months from start of NACT (BM3: n = 162/PB3: n = 141). Patients were included from 1997 to 2003 and followed until 2009 (or ten years follow-up). DTC- and CTC-status were determined by morphological evaluation of immunocytochemically detected cytokeratin-positive cells. The prognostic significance of DTCs/CTCs was assessed by univariate and multivariate Cox-regression analyses. Before NACT, DTCs and CTCs were detected in 21.2% and 4.9% of the patients, respectively. At surgery, 15.9% and 1.4% had DTC- and CTC-presence, compared to 26.5% and 4.3% at 12 months from start of NACT. Of patients for whom DTC results both before NACT and at 12 months were available, concordant results were observed in 68%, and 14 out of 65 had positive DTC-status at both time points. Presence of ≥ 1 DTC 12 months from start of NACT, but not at other time points, predicted reduced disease-free survival (DFS; HR 2.3, p = 0.003), breast cancer-specific survival (BCSS; HR 3.0, p &lt; 0.001) and overall survival (OS; HR 2.8, p &lt; 0.001). Before NACT, presence of ≥ 3 DTCs was also associated with unfavorable outcome, and reduced BCSS was observed for CTC-positive patients (HR 2.2, p = 0.046). In multivariate analysis, DTC status (&lt;/≥ 1 DTC) at 12 months after start of NACT remained as a prognostic factor for both DFS (HR 2.2, p = 0.005), BCSS (HR 2.6, p = 0.002) and OS (HR 2.6, p = 0.002). The survival for patients with change in DTC-status was determined by the DTC-status at 12 months. Presence of DTCs after NACT indicated high risk for relapse and death, irrespective of the DTC-status before treatment. The results supports the potential use of DTC analysis as a monitoring tool during follow up, for selection of patients to secondary treatment intervention within clinical trials.
      datePublished:2012-08-14T00:00:00Z
      dateModified:2012-08-14T00:00:00Z
      pageStart:1
      pageEnd:13
      license:http://creativecommons.org/licenses/by/2.0/
      sameAs:https://doi.org/10.1186/bcr3242
      keywords:
         Overall Survival
         Advanced Breast Cancer
         Circulate Tumor Cell
         Bone Marrow Aspiration
         Disseminate Tumor Cell
         Cancer Research
         Oncology
         Surgical Oncology
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fbcr3242/MediaObjects/13058_2012_3049_Fig1_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fbcr3242/MediaObjects/13058_2012_3049_Fig2_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fbcr3242/MediaObjects/13058_2012_3049_Fig3_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fbcr3242/MediaObjects/13058_2012_3049_Fig4_HTML.jpg
      isPartOf:
         name:Breast Cancer Research
         issn:
            1465-542X
         volumeNumber:14
         type:
            Periodical
            PublicationVolume
      publisher:
         name:BioMed Central
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Randi R Mathiesen
            affiliation:
                  name:Institute for Cancer Research, Oslo University Hospital, The Radium Hospital
                  address:
                     name:Department of Genetics, Institute for Cancer Research, Oslo University Hospital, The Radium Hospital, Oslo, Norway
                     type:PostalAddress
                  type:Organization
                  name:Oslo University Hospital
                  address:
                     name:Division of Surgery and Cancer Medicine, Department of Oncology, Oslo University Hospital, Oslo, Norway
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Elin Borgen
            affiliation:
                  name:Oslo University Hospital, The Radium Hospital
                  address:
                     name:Department of Pathology, Oslo University Hospital, The Radium Hospital, Oslo, Norway
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Anne Renolen
            affiliation:
                  name:Oslo University Hospital, The Radium Hospital
                  address:
                     name:Department of Pathology, Oslo University Hospital, The Radium Hospital, Oslo, Norway
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Erik Løkkevik
            affiliation:
                  name:Oslo University Hospital
                  address:
                     name:Division of Surgery and Cancer Medicine, Department of Oncology, Oslo University Hospital, Oslo, Norway
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Jahn M Nesland
            affiliation:
                  name:Oslo University Hospital, The Radium Hospital
                  address:
                     name:Department of Pathology, Oslo University Hospital, The Radium Hospital, Oslo, Norway
                     type:PostalAddress
                  type:Organization
                  name:University of Oslo
                  address:
                     name:Institute of Clinical medicine, Faculty of Medicine, University of Oslo, Oslo, Norway
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Gun Anker
            affiliation:
                  name:University of Bergen
                  address:
                     name:Section of Oncology, Institute of Medicine, University of Bergen, Bergen, Norway
                     type:PostalAddress
                  type:Organization
                  name:Haukeland University Hospital
                  address:
                     name:Department of Oncology, Haukeland University Hospital, Bergen, Norway
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Bjørn Østenstad
            affiliation:
                  name:Oslo University Hospital
                  address:
                     name:Division of Surgery and Cancer Medicine, Department of Oncology, Oslo University Hospital, Oslo, Norway
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Steinar Lundgren
            affiliation:
                  name:St. Olav University Hospital
                  address:
                     name:Department of Oncology, St. Olav University Hospital, Trondheim, Norway
                     type:PostalAddress
                  type:Organization
                  name:Norwegian University of Science and Technology
                  address:
                     name:Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Terje Risberg
            affiliation:
                  name:University Hospital of Northern Norway and Institute of Clinical Medicine, University of Tromsø
                  address:
                     name:Department of Oncology, University Hospital of Northern Norway and Institute of Clinical Medicine, University of Tromsø, Tromsø, Norway
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Ingvil Mjaaland
            affiliation:
                  name:Stavanger University Hospital
                  address:
                     name:Division of Hematology and Oncology, Stavanger University Hospital, Stavanger, Norway
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Gunnar Kvalheim
            affiliation:
                  name:Oslo University Hospital
                  address:
                     name:Division of Surgery and Cancer Medicine, Department of Oncology, Oslo University Hospital, Oslo, Norway
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Per Eystein Lønning
            affiliation:
                  name:University of Bergen
                  address:
                     name:Section of Oncology, Institute of Medicine, University of Bergen, Bergen, Norway
                     type:PostalAddress
                  type:Organization
                  name:Haukeland University Hospital
                  address:
                     name:Department of Oncology, Haukeland University Hospital, Bergen, Norway
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Bjørn Naume
            affiliation:
                  name:Oslo University Hospital
                  address:
                     name:Division of Surgery and Cancer Medicine, Department of Oncology, Oslo University Hospital, Oslo, Norway
                     type:PostalAddress
                  type:Organization
                  name:University of Oslo
                  address:
                     name:Institute of Clinical medicine, Faculty of Medicine, University of Oslo, Oslo, Norway
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:Breast Cancer Research
      issn:
         1465-542X
      volumeNumber:14
Organization:
      name:BioMed Central
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Institute for Cancer Research, Oslo University Hospital, The Radium Hospital
      address:
         name:Department of Genetics, Institute for Cancer Research, Oslo University Hospital, The Radium Hospital, Oslo, Norway
         type:PostalAddress
      name:Oslo University Hospital
      address:
         name:Division of Surgery and Cancer Medicine, Department of Oncology, Oslo University Hospital, Oslo, Norway
         type:PostalAddress
      name:Oslo University Hospital, The Radium Hospital
      address:
         name:Department of Pathology, Oslo University Hospital, The Radium Hospital, Oslo, Norway
         type:PostalAddress
      name:Oslo University Hospital, The Radium Hospital
      address:
         name:Department of Pathology, Oslo University Hospital, The Radium Hospital, Oslo, Norway
         type:PostalAddress
      name:Oslo University Hospital
      address:
         name:Division of Surgery and Cancer Medicine, Department of Oncology, Oslo University Hospital, Oslo, Norway
         type:PostalAddress
      name:Oslo University Hospital, The Radium Hospital
      address:
         name:Department of Pathology, Oslo University Hospital, The Radium Hospital, Oslo, Norway
         type:PostalAddress
      name:University of Oslo
      address:
         name:Institute of Clinical medicine, Faculty of Medicine, University of Oslo, Oslo, Norway
         type:PostalAddress
      name:University of Bergen
      address:
         name:Section of Oncology, Institute of Medicine, University of Bergen, Bergen, Norway
         type:PostalAddress
      name:Haukeland University Hospital
      address:
         name:Department of Oncology, Haukeland University Hospital, Bergen, Norway
         type:PostalAddress
      name:Oslo University Hospital
      address:
         name:Division of Surgery and Cancer Medicine, Department of Oncology, Oslo University Hospital, Oslo, Norway
         type:PostalAddress
      name:St. Olav University Hospital
      address:
         name:Department of Oncology, St. Olav University Hospital, Trondheim, Norway
         type:PostalAddress
      name:Norwegian University of Science and Technology
      address:
         name:Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway
         type:PostalAddress
      name:University Hospital of Northern Norway and Institute of Clinical Medicine, University of Tromsø
      address:
         name:Department of Oncology, University Hospital of Northern Norway and Institute of Clinical Medicine, University of Tromsø, Tromsø, Norway
         type:PostalAddress
      name:Stavanger University Hospital
      address:
         name:Division of Hematology and Oncology, Stavanger University Hospital, Stavanger, Norway
         type:PostalAddress
      name:Oslo University Hospital
      address:
         name:Division of Surgery and Cancer Medicine, Department of Oncology, Oslo University Hospital, Oslo, Norway
         type:PostalAddress
      name:University of Bergen
      address:
         name:Section of Oncology, Institute of Medicine, University of Bergen, Bergen, Norway
         type:PostalAddress
      name:Haukeland University Hospital
      address:
         name:Department of Oncology, Haukeland University Hospital, Bergen, Norway
         type:PostalAddress
      name:Oslo University Hospital
      address:
         name:Division of Surgery and Cancer Medicine, Department of Oncology, Oslo University Hospital, Oslo, Norway
         type:PostalAddress
      name:University of Oslo
      address:
         name:Institute of Clinical medicine, Faculty of Medicine, University of Oslo, Oslo, Norway
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Randi R Mathiesen
      affiliation:
            name:Institute for Cancer Research, Oslo University Hospital, The Radium Hospital
            address:
               name:Department of Genetics, Institute for Cancer Research, Oslo University Hospital, The Radium Hospital, Oslo, Norway
               type:PostalAddress
            type:Organization
            name:Oslo University Hospital
            address:
               name:Division of Surgery and Cancer Medicine, Department of Oncology, Oslo University Hospital, Oslo, Norway
               type:PostalAddress
            type:Organization
      name:Elin Borgen
      affiliation:
            name:Oslo University Hospital, The Radium Hospital
            address:
               name:Department of Pathology, Oslo University Hospital, The Radium Hospital, Oslo, Norway
               type:PostalAddress
            type:Organization
      name:Anne Renolen
      affiliation:
            name:Oslo University Hospital, The Radium Hospital
            address:
               name:Department of Pathology, Oslo University Hospital, The Radium Hospital, Oslo, Norway
               type:PostalAddress
            type:Organization
      name:Erik Løkkevik
      affiliation:
            name:Oslo University Hospital
            address:
               name:Division of Surgery and Cancer Medicine, Department of Oncology, Oslo University Hospital, Oslo, Norway
               type:PostalAddress
            type:Organization
      name:Jahn M Nesland
      affiliation:
            name:Oslo University Hospital, The Radium Hospital
            address:
               name:Department of Pathology, Oslo University Hospital, The Radium Hospital, Oslo, Norway
               type:PostalAddress
            type:Organization
            name:University of Oslo
            address:
               name:Institute of Clinical medicine, Faculty of Medicine, University of Oslo, Oslo, Norway
               type:PostalAddress
            type:Organization
      name:Gun Anker
      affiliation:
            name:University of Bergen
            address:
               name:Section of Oncology, Institute of Medicine, University of Bergen, Bergen, Norway
               type:PostalAddress
            type:Organization
            name:Haukeland University Hospital
            address:
               name:Department of Oncology, Haukeland University Hospital, Bergen, Norway
               type:PostalAddress
            type:Organization
      name:Bjørn Østenstad
      affiliation:
            name:Oslo University Hospital
            address:
               name:Division of Surgery and Cancer Medicine, Department of Oncology, Oslo University Hospital, Oslo, Norway
               type:PostalAddress
            type:Organization
      name:Steinar Lundgren
      affiliation:
            name:St. Olav University Hospital
            address:
               name:Department of Oncology, St. Olav University Hospital, Trondheim, Norway
               type:PostalAddress
            type:Organization
            name:Norwegian University of Science and Technology
            address:
               name:Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway
               type:PostalAddress
            type:Organization
      name:Terje Risberg
      affiliation:
            name:University Hospital of Northern Norway and Institute of Clinical Medicine, University of Tromsø
            address:
               name:Department of Oncology, University Hospital of Northern Norway and Institute of Clinical Medicine, University of Tromsø, Tromsø, Norway
               type:PostalAddress
            type:Organization
      name:Ingvil Mjaaland
      affiliation:
            name:Stavanger University Hospital
            address:
               name:Division of Hematology and Oncology, Stavanger University Hospital, Stavanger, Norway
               type:PostalAddress
            type:Organization
      name:Gunnar Kvalheim
      affiliation:
            name:Oslo University Hospital
            address:
               name:Division of Surgery and Cancer Medicine, Department of Oncology, Oslo University Hospital, Oslo, Norway
               type:PostalAddress
            type:Organization
      name:Per Eystein Lønning
      affiliation:
            name:University of Bergen
            address:
               name:Section of Oncology, Institute of Medicine, University of Bergen, Bergen, Norway
               type:PostalAddress
            type:Organization
            name:Haukeland University Hospital
            address:
               name:Department of Oncology, Haukeland University Hospital, Bergen, Norway
               type:PostalAddress
            type:Organization
      name:Bjørn Naume
      affiliation:
            name:Oslo University Hospital
            address:
               name:Division of Surgery and Cancer Medicine, Department of Oncology, Oslo University Hospital, Oslo, Norway
               type:PostalAddress
            type:Organization
            name:University of Oslo
            address:
               name:Institute of Clinical medicine, Faculty of Medicine, University of Oslo, Oslo, Norway
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Department of Genetics, Institute for Cancer Research, Oslo University Hospital, The Radium Hospital, Oslo, Norway
      name:Division of Surgery and Cancer Medicine, Department of Oncology, Oslo University Hospital, Oslo, Norway
      name:Department of Pathology, Oslo University Hospital, The Radium Hospital, Oslo, Norway
      name:Department of Pathology, Oslo University Hospital, The Radium Hospital, Oslo, Norway
      name:Division of Surgery and Cancer Medicine, Department of Oncology, Oslo University Hospital, Oslo, Norway
      name:Department of Pathology, Oslo University Hospital, The Radium Hospital, Oslo, Norway
      name:Institute of Clinical medicine, Faculty of Medicine, University of Oslo, Oslo, Norway
      name:Section of Oncology, Institute of Medicine, University of Bergen, Bergen, Norway
      name:Department of Oncology, Haukeland University Hospital, Bergen, Norway
      name:Division of Surgery and Cancer Medicine, Department of Oncology, Oslo University Hospital, Oslo, Norway
      name:Department of Oncology, St. Olav University Hospital, Trondheim, Norway
      name:Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway
      name:Department of Oncology, University Hospital of Northern Norway and Institute of Clinical Medicine, University of Tromsø, Tromsø, Norway
      name:Division of Hematology and Oncology, Stavanger University Hospital, Stavanger, Norway
      name:Division of Surgery and Cancer Medicine, Department of Oncology, Oslo University Hospital, Oslo, Norway
      name:Section of Oncology, Institute of Medicine, University of Bergen, Bergen, Norway
      name:Department of Oncology, Haukeland University Hospital, Bergen, Norway
      name:Division of Surgery and Cancer Medicine, Department of Oncology, Oslo University Hospital, Oslo, Norway
      name:Institute of Clinical medicine, Faculty of Medicine, University of Oslo, Oslo, Norway

External Links {🔗}(179)

Analytics and Tracking {📊}

  • Google Tag Manager

Libraries {📚}

  • Clipboard.js
  • Prism.js

CDN Services {📦}

  • Crossref

5.38s.